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Abstract
The cDNA encoding an intron 5-inserted form of the erythropoietin receptor (I5Epo-R) has been cloned from rat. DNA
sequence analysis reveals that the insertion of intron 5, which consists of 79 bp, causes a shift in reading frame and results in
termination in the region of exon 7. The deduced amino acid sequence is composed of 316 amino acid residues, which is a
molecular weight of 34 220. To study the function of rat I5Epo-R, we established a Chinese hamster ovary cell line expressing
rat I5Epo-R. Western blot analysis and binding studies with 125I-recombinant human erythropoietin showed that the
transfected cells expressed rat I5Epo-R with a molecular size of 36 kDa as a membrane-bound form, but not as a soluble
form, and had a single class of binding sites with a Kd of 700 pM. z 1998 Elsevier Science B.V.
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1. Introduction
Erythropoietin (Epo), which is a cytokine speci¢-
cally stimulating the di¡erentiation and proliferation
of erythroid progenitor cells and supporting their
survival, transduces its signal through a speci¢c re-
ceptor, Epo-R, on the cell surface [1^3]. Molecular
cloning studies have provided information for the
structure and function of Epo-R [4^7]. The Epo-R
gene is composed of eight exons. The ¢rst ¢ve exons
primarily encode the extracellular domain, whereas
the regions encoding the single transmembrane do-
main and the intracellular domain are located in
exon 6 and exons 7 and 8, respectively.
Recently, several studies have reported the ex-
istence of alternatively spliced forms of Epo-R
mRNA, some of which encode the membrane-bound
forms as well as the authentic form. F4N murine
erythroleukemia cells express a truncated Epo-R
composed of the extracellular and transmembrane
domains and four amino acids in the intracellular
domain, which results from the failure to splice out
introns 6 and 7 [8]. An aberrant Epo-R mRNA re-
sulting from the insertion of intron between exons 7
and 8 is found in normal human bone marrow
mononuclear cells, and its recombinant protein lacks
abilities to transmit a mitogenic signal and to prevent
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apoptosis [9,10]. In contrast, an aberrant form of
murine Epo-R mRNA, which is generated by the
retention of intron 5 and part of intron 6, encodes
a soluble form of Epo-R, because of the lack of the
transmembrane and cytoplasmic domains due to the
appearance of a TGA stop codon in the sequence of
intron 5 [5,11]. An aberrant form of human Epo-R
mRNA resulting from insertion of part of intron 4 is
translated as a soluble protein lacking the ability for
binding Epo [12,13]. Furthermore, two proteins re-
active to anti-Epo-R antibodies have been found in
human serum [14,15]. However, physiological func-
tions of these aberrant Epo-Rs have not been well
clari¢ed.
We have reported that an intron 5-inserted form of
Epo-R (I5Epo-R) mRNA, in addition to the authen-
tic form, is expressed in brain capillary endothelial
cells and erythroid progenitor cells in rats [16]. In the
present study, we have isolated cDNA for the I5Epo-
R mRNA from rat brain capillary endothelial cells,
and report that the insertion of intron 5, which con-
sists of 79 bp, causes a shift in reading frame and
results in termination in the region of exon 7 in rat.
Furthermore, we have established a Chinese hamster
ovary cell line expressing rat I5Epo-R, and show that
rat I5Epo-R has the ability to bind Epo and is a
membrane-bound form (but not a soluble form),
although the insertion of intron 5 causes a shift in
reading frame in exon 6 in which the transmembrane
domain is encoded in the authentic Epo-R.
2. Materials and methods
2.1. Materials
The recombinant human Epo (rHuEpo: 200 000
IU/mg) and the mammalian expression vector
pMDR901 used throughout the present study were
kindly provided by Kirin Brewery (Gunma, Japan)
and BTG USA Inc. (Gulph Mills, PA, USA), respec-
tively. Epo-¢xed gel (6 mg ¢xed Epo/ml gel) was
prepared using rHuEpo (4 mg) and activated CH
Sepharose 4B gel (0.5 ml) (Pharmacia Biotech) ac-
cording to the method of Nagao et al. [17]. Anti-
rat Epo-R antibodies were raised in a rabbit by in-
jecting a peptide (ASSPSLPDPKFESKAC), and pu-
ri¢ed by using a protein-A Sepharose. The under-
lined amino acid sequence corresponds to the N-
terminal sequence of rat Epo-R [18] and the carboxyl
terminal cysteine was designed to couple with a car-
rier protein, keyhole limpet hemocyanin.
2.2. Primers
The nucleotide sequences of the primers used cor-
respond to the nucleotide sequences of rat Epo-R
[18] and rat I5Epo-R in the present study, and are
summarized in Table 1.
2.3. Isolation of rat I5Epo-R cDNA
Rat brain capillary endothelial cells were isolated
as described previously [16]. Total RNA was pre-
pared by an acid guanidium thiocyanate-phenol-
chloroform extraction method [19]. The I5Epo-R
cDNA was obtained with the reverse transcription-
polymerase chain reaction (RT-PCR) method using
primers RE1 and RE7. The RT-PCR was performed
as described previously [16]. Ampli¢cation was per-
formed with 5 min at 94‡C for denaturation, fol-
lowed by 30 cycles of 1 min at 94‡C for denaturation,
2 min at 55‡C for annealing, 1 min at 72‡C for elon-
gation, followed by a single extension of 10 min at
72‡C. The RT-PCR product was cloned into pGEM-
T vector (Promega) and sequenced. The plasmid was
named pGI5ER.
2.4. Construction of expression vectors
To introduce a typical Kozak consensus sequence,
5P-GCC(G/A)CC-3P [20], into rat I5Epo-R cDNA,
the PCR of the EcoRI-digested fragment of pGI5ER
was performed using the primers K1 and NE7 as
described above except for annealing at 40‡C. The
PCR product was cloned into pGEM-T vector and
sequenced. The NotI-digested fragment of the plas-
mid obtained was subcloned into the NotI-digested
sites of pMDR901 [21] and termed pI5ER.
The mutation in the sequence of intron 5 of rat
I5Epo-R cDNA was generated by PCR. Two frag-
ments were prepared by PCR using the NotI-digested
fragment of pI5ER as a template and the following
combination of primers: (a) primers K2 and M2 and
(b) primers M1 and NE7. Each PCR product was
puri¢ed and mixed. The I5Epo-R cDNA with muta-
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tion was generated by PCR using primers K2 and
NE7 and the mixture as a template. The PCR was
performed with annealing at 40‡C. The PCR product
was cloned into pGEM-T vector, sequenced and
termed pGmI5ER. The NotI-digested fragment of
pGmI5ER was subcloned into the NotI sites of
pMDR901 to construct an expression vector,
pmI5ER. Furthermore, the PCR was performed us-
ing the NotI-digested fragment of pGmI5ER and
primers K2 and MI5 to generate cDNA for a trun-
cated form of rat Epo-R by mimicking murine
I5Epo-R cDNA. The NotI-digested fragment of the
PCR product, which was cloned into pGEM-T vec-
tor and sequenced, was subcloned into the NotI sites
of pMDR901 to construct an expression vector,
pmsI5ER.
2.5. Cell culture and DNA transfection
Chinese hamster ovary cells de¢cient in dihydrofo-
late reductase activity (CHO-dhfr3 cells) were
maintained in K-minimum essential medium with
ribonucleosides and deoxyribonucleosides (Gibco)
supplemented with 10% fetal calf serum, 100 U/ml
penicillin and 100 Wg/ml streptomycin at 37‡C in a
5% CO2/95% air atmosphere at 100% humidity be-
fore transfection. After plasmid DNAs were trans-
fected into these cells by lipofection using Tfx-50
(Promega) according to the manufacturer’s instruc-
tions, the positive clones were selected in K-minimum
essential medium without ribonucleosides and deoxy-
ribonucleosides supplemented with 10% dialyzed fe-
tal calf serum and antibiotics. Subsequent expression
was ampli¢ed by selection of clones in increasing
concentrations of methotrexate from 20^100 nM.
2.6. Detection of I5Epo-R mRNA
Total RNA from the transfected cells were pre-
pared and the RT-PCR was performed using primers
E5 and E7 with annealing at 55‡C. The ampli¢ed
products were detected by Southern blot. The 903-
bp Epo-R cDNA fragment labeled with digoxigenin-
11-dUTP was used as a probe [16].
2.7. Detection of I5Epo-R in transfectants
Transfected cells were cultured to con£uency (ap-
proximately 7U106 cells on a 100-mm dish). Condi-
tioned media (8 ml) was withdrawn from the culture
and added HEPES-NaOH, pH 7.5, phenylmethylsul-
fonyl £uoride (PMSF), leupeptin and EDTA at the
¢nal concentrations of 100 mM, 0.1 mM, 10 WM and
1 mM, respectively. To remove cell debris, condi-
tioned media was centrifuged at 18 000Ug for
20 min at 4‡C, and the supernatant was used as a
sample solution. After the withdrawal of the media,
remaining cells were washed with ice-cold phosphate-
bu¡ered saline (PBS), and lysed with 2 ml of 100 mM
HEPES-NaOH bu¡er, pH 7.5, containing 0.5% (w/v)
Nonidet P-40, 0.1 mM PMSF, 10 WM leupeptin and
1 mM EDTA at 4‡C. After removal of cell debris by
centrifugation (18 000Ug, 20 min), the cell lysate ob-
tained was used as a sample solution. Both sample
solutions from the conditioned media and the cell
lysate were incubated with 25 Wl of the Epo-¢xed
gel at 4‡C overnight. After washing three times
with ice-cold lysis bu¡er, the gel was boiled in 50 Wl
of 100 mM Tris-HCl, pH 6.8, containing 2% SDS
and 1.4 M 2-mercaptoethanol for 5 min and centri-
fuged at 18 000Ug for 5 min. The supernatant (25 Wl :
the mock- or the pmI5ER-transfected cells ; 5 Wl : the
pmsI5ER-transfected cells) was subjected to SDS-
PAGE (12.5%) and then analyzed by immunoblot-
ting using rabbit anti-N-terminal rat Epo-R antibod-
ies. The detection assay was performed using POD
Immunostain Set (Wako Pure Chemical Industries,
Osaka, Japan).
2.8. Binding studies
The 125I-rHuEpo was used at a speci¢c activity of
670 Ci/mmol and retained full biological activity [16].
The binding of 125I-rHuEpo to the transfected cells
was assayed as described previously [16] except that
incubations for binding were performed at 4‡C for
2 h using 3U105 cells. Speci¢c binding was obtained
by subtracting non-speci¢c binding, which was deter-
mined in the presence of 250-fold unlabeled rHuEpo,
from total binding.
2.9. Cross-linking experiments
Con£uent cells cultured in the 60-mm dishes were
washed twice with ice-cold binding bu¡er (Hanks’
solution containing 10 mM HEPES, pH 7.5, and
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0.1% bovine serum albumin) and incubated with
1 nM 125I-rHuEpo (2200 Ci/mmol) in the bu¡er
(1.5 ml) in the presence or absence of 200-fold unla-
beled rHuEpo at 4‡C for 3 h. The cells were washed
twice with ice-cold PBS and then incubated in 2 ml
of PBS containing 20 mM HEPES, pH 7.5, and
1mM disuccinimidyl suberate (DSS), disuccinimidyl
glutarate (DSG) or ethylene glycolbis[succinimidyl-
succinate] (EGS) at 4‡C for 1 h. The reaction was
stopped by the addition of 60 Wl of 1 M Tris-HCl,
pH 7.5, and after washing twice with PBS the cells
were lysed with 100 mM HEPES-NaOH bu¡er, pH
7.5, containing 0.5% (w/v) Nonidet P-40, 0.1 mM
PMSF, 10 WM leupeptin and 1 mM EDTA. After
removal of cell debris by centrifugation at
18 000Ug for 20 min, the supernatant obtained was
subjected to SDS-PAGE (7.5% gel), and radioactive
proteins in the gel were detected on an X-ray ¢lm.
The supernatant was also incubated with non-immu-
nized rabbit IgG (10 Wg) at 4‡C for 1 h, followed by
the addition of 15 Wl of protein A-Sepharose resin.
After 1 h incubation, the resin was removed by cen-
trifugation, and the supernatant was incubated with
4 Wg rabbit anti-N-terminal rat Epo-R antibodies in
the presence or absence of 50 Wg of an N-terminal
peptide used for raising the antibodies at 4‡C for 1 h,
and then mixed with 15 Wl of protein A-Sepharose
resin overnight at 4‡C. The resin was washed three
times with ice-cold PBS containing 0.5% Nonidet P-
40, and proteins bound on the resin were eluted with
100 mM Tris-HCl, pH 6.8, containing 2% SDS and
1.4 M 2-mercaptoethanol, at 100‡C. These proteins
were separated by SDS-PAGE (7.5% gel), and radio-
active ones in the gel were detected on an X-ray ¢lm.
3. Results
3.1. Nucleotide sequence of rat I5Epo-R
A cDNA clone for an abnormal form of Epo-R
mRNA resulting from retention of intron 5 was iso-
lated from rat brain capillary endothelial cells. Fig.
1A shows the nucleotide sequence of rat I5Epo-R
cDNA and its deduced amino acid sequence. As
shown in Fig. 1B, there are some di¡erences in the
sequence of intron 5 for Epo-R gene among rat (the
present work), mouse [5] and human [6]. In rat, the
insertion of intron 5 with 79 bp results in a shift in
reading frame, and a TGA stop codon appears in the
region of exon 7. Thus, its translational product with
316 amino acid residues consists of the N-terminal
signal peptide and extracellular domain in the au-
thentic Epo-R (which are encoded in exons 1 to 5),
and an aberrant C-terminal tail (which comprises 71
amino acid residues) and calculated to have a molec-
ular weight of 34 220. The aberrant form of Epo-R
retains one N-glycosylation site and one Trp-Ser-X-
Trp-Ser (W-S-X-W-S) motif, which commonly exists
outside the transmembrane domain of cytokine re-
ceptors and is reported to be essential for binding
Epo [22,23].
3.2. I5Epo-R mRNA in the transfected cells
To express rat I5Epo-R in CHO-dhfr3 cells, an
expression vector, pI5ER, was constructed and intro-
duced into the cells. When total RNA obtained from
the transfected cells was subjected to the RT-PCR
using primers E5 and E7, Southern blot analysis de-
tected one major PCR product with a lower size
(about 270 bp) and one minor one with a higher
size (about 350 bp) (Fig. 2, lane 2). The transcrip-
tional product of pI5ER with full length should give
a product with 346 bp in the RT-PCR, whereas it is
predicted that the removal of a sequence correspond-
ing to intron 5 from the transcriptional product by
the splicing mechanism results in the appearance of a
PCR product with 267 bp. Thus, these results suggest
that splicing of the transcriptional product of pI5ER
occurs in the transfected cells. Introns have consen-
sus sequences at the 5P splice site, branch site and 3P
splice site, and complementarity between the sequen-
ces at the 5P splice site and branch site is essential for
intron removal in the nuclear mRNA splicing proc-
ess [24]. To avoid the splicing, site-directed mutagen-
esis was introduced into I5ER using mutation pri-
mers, M1 and M2 (Table 1), at the 5P splice site
and branch site (the mutagenesis does not result in
any changes in amino acid level). When the con-
structed expression vector, termed pmI5ER, was in-
troduced into CHO-dhfr3 cells and its transcription-
al product was analyzed by the RT-PCR, a product
with about 350 bp alone was detected (Fig. 2, lane 3).
The transfected cells, termed CMm1 cells, were used
for characterization of rat I5Epo-R.
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Fig. 1. Nucleotide sequence of rat I5Epo-R. A: The nucleotide sequence and its deduced amino acid sequence of rat I5Epo-R. The
nucleotide sequence of rat I5Epo-R is shown in the ¢rst line. The nucleotide sequence with lower case letters indicates the region of
intron 5. The deduced amino acid sequences of rat (R) and mouse (M) [5] are shown in the single-letter code below the nucleotide
sequence. The asterisk, the box and the dot represent the site of N-glycosylation, the region of the W-S-X-W-S motif and the stop
codon, respectively. B: Alignments of the nucleotide sequences of intron 5 of rat, murine and human Epo-R genes. The nucleotide
sequences of intron 5 for rat, murine [5] and human [6] Epo-R are represented as lower case letters in the ¢rst, second and third lines,
respectively. The dashes are inserted to achieve maximum identity. The underlined sequence is a TGA stop codon in murine I5Epo-R.
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3.3. Expression of I5Epo-R in the transfected cells
The conditioned medium and cell lysate prepared
from CMm1 cells were incubated with an Epo-¢xed
CH-Sepharose resin, and proteins bound to the resin
were analyzed by SDS-PAGE followed by immuno-
blotting using antibodies against rat Epo-R. As
shown in Fig. 3, one immunoreactive protein band
with a molecular mass of 36 kDa was found in the
cell lysate (lane 4). In contrast, no bands were ob-
served when the conditioned medium was analyzed
(lane 3). To detect secreted proteins which were re-
active to the anti-Epo-R antibodies but not capable
of binding Epo, CMm1 cells were cultured in the
presence of [35S]methionine, the conditioned medium
obtained was incubated with the antibodies, and im-
Fig. 4. Binding of radiolabeled rHuEpo to the transfected cells expressing rat I5Epo-R. A: Binding of Epo to CMm1, RY11 or the
mock-transfected cells. The transfectants (3U105 cells) were incubated with 1 nM 125I-rHuEpo at 4‡C for 2 h in the absence (open
bars) and the presence (hatched bars) of 200-fold unlabeled rHuEpo. Results are means þ S.E.M. of three experiments performed in
triplicate. B: Scatchard analysis of the binding of 125I-rHuEpo to CMm1. The inset represents the ligand saturation curves. Speci¢c
binding (b) was obtained by subtracting non-speci¢c binding (a) from total binding (E). Results are the mean of three experiments in
triplicate.
Fig. 3. Western blot analysis of rat I5Epo-R. The conditioned
medium (lanes 1, 3 and 5) and the lysate obtained from mock-
transfected (lanes 1 and 2), CMm1 (lanes 3 and 4) and RY11
(lanes 5 and 6) cells were incubated with an Epo-¢xed CH
Sepharose resin, and proteins bound to the resin were analyzed
by SDS-PAGE followed by immunoblotting using anti-Epo-R
antibodies.
Fig. 2. Detection of rat I5Epo-R mRNA. Total RNAs were
prepared from transfected cells and the RT-PCR was performed
using primers E5 and E7. The RT-PCR products were detected
by Southern blot analysis. Lanes 1, 2 and 3 show the RT-PCR
products from the mock-transfected cells, the pI5ER-transfected
cells and the pmI5ER-transfected cells, respectively.
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munoprecipitated proteins using protein A-Sephar-
ose were analyzed by SDS-PAGE followed by auto-
radiography. However, no radioactive bands were
observed (data not shown). Furthermore, to design
a truncated mutant of I5Epo-R, a TGA stop codon
was introduced into the intron 5-corresponding se-
quence of pmI5ER by the deletion of c at position
55 of the intron 5 sequence (see Table 1 and Fig. 1).
The constructed expression vector, pmsI5ER, was
introduced into CHO cells to express the truncated
mutant, and a positive clone was isolated and termed
RY11 cells. Western blot analysis using the anti-Epo-
R antibodies showed that RY11 cells secreted an
immunoreactive protein with 33 kDa in the condi-
tioned medium (Fig. 3, lane 5). In addition, an im-
munoreactive protein band (31.5 kDa) was observed
in the lysate of RY11 cells (lane 6), but the intensity
of the band was obviously lower than that of the 33-
kDa band observed in the conditioned medium.
3.4. Binding of Epo to the transfected cells
As shown in Fig. 4A, speci¢c binding of 125I-
rHuEpo was observed on the surface of CMm1 cells
(but not on the mock-transfected cells). A Scatchard
plot analysis (Fig. 4B; the inset represents the ligand-
saturation curves) showed that these cells possessed a
single class of Epo-binding sites, and the Kd and the
number of the binding sites were 700 pM and 7500
sites/cell, respectively. These results indicate that rat
I5Epo-R was expressed as a membrane-bound pro-
tein capable to bind Epo on the surface of CMm1
cells. In contrast, speci¢c binding of 125I-rHuEpo was
not observed on RY11 cells (Fig. 4A), although these
cells expressed two proteins capable to bind the Epo-
¢xed resin and reactive to the anti-Epo-R antibodies,
one of which (31.5-kDa protein) was found in the
lysate of the cells (the other with 33 kDa was found
outside the cells) (see Fig. 3). It is indicated that the
Fig. 5. Cross-linking of 125I-rHuEpo with rat I5Epo-R. A:
Analysis of cross-linked products. CMm1 cells were incubated
with 1 nM 125I-rHuEpo in the absence (lanes 1, 3 and 5) or
presence (lanes 2, 4 and 6) of 200 nM unlabeled rHuEpo, and
then exposed to DSS (lanes 1 and 2), DSG (lanes 3 and 4) or
EGS (lanes 5 and 6). The cell lysate obtained was subjected to
SDS-PAGE and radioactive proteins in the lysate were detected
by autoradiography. B: Immunoprecipitation of cross-linked
products. Lysate obtained from CMm1 cells which had been ex-
posed to 1 nM 125I-rHuEpo and then to DSS, was incubated
with anti-N-terminal Epo-R antibodies with (lane 2) or without
(lane 1) 50 Wg of an N-terminal peptide used for raising the
antibodies in the presence of protein A-Sepharose. Immunopre-
cipitated proteins obtained were analyzed by SDS-PAGE fol-
lowed by autoradiography.
Table 1
Oligonucleotide primers used for PCR of Epo-R cDNA
The nucleotide sequences in the primers RE1, RE7, E5 and E7
correspond to the rat Epo-R cDNA sequence [18]. The nucleo-
tide sequences in the primers K1, K2, M1, M2, NE7 and MI5
correspond to the rat I5Epo-R cDNA sequence in Fig. 1. The
underlines and the lower case letters in the sequences were de-
signed for NotI or EcoRI restriction sites and a typical Kozak
consensus sequence, respectively. The asterisks in the primers
M1 and M2 represent the sites of point mutation and the nu-
cleotides corresponding to the authentic sequence are shown in
parentheses. The nucleotide sequence in the primer MI5 has a
deleted G in parentheses from the authentic sequence on the
basis of the nucleotide sequence of intron 5 in mouse as shown
in Fig. 1B.
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truncated mutant of I5Epo-R did not locate on the
plasma membrane of RY11 cells (a large part was
secreted outside these cells and a small part remained
inside).
3.5. Detection of cross-linked products
The radioiodinated Epo was incubated with
CMm1 cells, followed by treatment with DSS,
DSG or EGS. As shown in Fig. 5A, each cross-linker
used resulted in one major cross-linked product with
a molecular mass of 70 kDa (lanes 1, 3 and 5). Ra-
dioactive cross-linked products were not detected
when cross-linking was performed in the presence
of an excess amount of unlabeled Epo (lanes 2, 4
and 6). Furthermore, the cross-linked product ob-
tained with DSS was con¢rmed to be reactive to
the anti-Epo-R antibodies (Fig. 5B). Since the mo-
lecular mass of rat I5Epo-R expressed on the surface
of CMm1 cells is estimated to be 36 kDa (see Fig. 3),
it is suggested that the cross-linked product is com-
posed of one molecule each of rat I5Epo-R and Epo
(34 kDa).
4. Discussion
Aberrant soluble forms of the cytokine receptors,
which result from the lack of the transmembrane
domain by alternative splicing or from the release
of the extracellular domain of the authentic mem-
brane-bound receptors by proteolytic cleavage have
been found in biological £uids [25]. Serum soluble
forms for interleukin-2K receptor [26,27], tumor ne-
crosis factor receptor [28] and interleukin-6 receptor
[29] are elevated in certain disease states, suggesting
that these aberrant forms of the cytokine receptors
are associated with certain diseases and can be used
as markers of disease activity.
We have reported that brain capillary endothelial
cells and erythroid progenitor cells in rats express an
intron 5-inserted form of Epo-R mRNA, in addition
to the authentic form [16]. Sequencing data (Fig. 1)
reveal that the insertion of intron 5, which consists of
79 bp, causes a shift in reading frame and results in
termination in the region of exon 7. It is thus pre-
dicted that in rat I5Epo-R the extracellular domain
of the authentic receptor is retained completely
whereas the transmembrane and intracellular do-
mains are substituted by an aberrant C-terminal
tail composed of 71 amino acid residues. Rat
I5Epo-R, when expressed in CHO cells, appeared
as a membrane-bound protein on the surface of these
cells (but not as a soluble protein excreted outside
(Figs. 3 and 4)), even though rat I5Epo-R lacks the
transmembrane domain of the authentic receptor. An
intron 5-inserted form of Epo-R mRNA has also
been found in mouse, and its translational product
(murine I5Epo-R), in contrast to rat I5Epo-R, is
reported to be secreted extracellularly as a soluble
receptor for Epo [5,11]. The structure of murine
I5Epo-R closely resembles that of rat I5Epo-R with
the exception that murine I5Epo-R has a shorter C-
terminal tail (composed of 20 amino acid residues)
compared with that of rat I5Epo-R. It is thus
thought that the relatively long C-terminal tail of
rat I5Epo-R is important to anchor the receptor to
plasma membrane. This notion is supported by our
observation that a truncated mutant of rat I5Epo-R,
having a C-terminal tail of 20 amino acid residues,
does not retain on plasma membrane and is mainly
secreted outside the cells (Figs. 3 and 4).
Binding a⁄nity of the authentic Epo-R varies
greatly with cell types in which the receptor is ex-
pressed [30,31]. In certain types of cells such as rat
erythroid progenitor cells [18] and TSA8 cells [32],
two di¡erent binding sites with high and low a⁄n-
ities are observed, and it is proposed that in these
cells Epo-R can bind Epo with a high a⁄nity (9^410
pM) when a cellular accessory component is associ-
ated [33]. In contrast, in other types of cells such as
Rauscher Red (5-1.5a) cells [34] and 707 cells [35], a
low a⁄nity binding site with Kd higher than 400 pM
alone is observed, presumably due to the lack of the
accessory component. The accessory component is
reported to occur in CHO cells even though these
cells do not express Epo-R [33]. However, CMm1
cells, which are CHO cells expressing rat I5Epo-R,
have a single class of Epo-binding sites with a Kd of
700 pM. Thus, the aberrant receptor may not have
the ability to associate with the accessory compo-
nent. This notion is supported by results obtained
by cross-linking experiments with DSS, DSG or
EGS (Fig. 5).
Epo-R possesses two conserved motifs, box 1 and
box 2, which are suggested to be essential for the
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activation of Jak protein tyrosine kinase, within the
membrane-proximal regions in the cytoplasmic do-
main, and the activation of Jak kinase is an impor-
tant step in signal transduction through Epo-R,
which lacks an intrinsic protein tyrosine kinase activ-
ity [36,37]. Since rat I5Epo-R does not possess amino
acid sequence corresponding to box 1 and box 2
(Fig. 1), it is reasonable to postulate that the aber-
rant receptor is not able to transduce signals in re-
sponse to ligand binding. It is thus thought that rat
I5Epo-R, when expressed on cells in which the au-
thentic Epo-R shows low a⁄nity binding alone (such
as placent cells [38], PC12 cells [18] and brain capil-
lary endothelial cells [16]), acts as a modulator for
the functions of Epo by competing the binding of
Epo with the authentic receptor.
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